AliveDx achieves IVDR-CE Mark for a multiplexed MosaiQ AiPlex Vasculitis (VAS) assay, designed to advance the testing of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides and Anti-GBM (Goodpasture’s) disease and improve time to results to support diagnosis of autoimmune vasculitis.
AliveDx, the global in vitro diagnostics company that aims to transform patient care, announces that the MosaiQ AiPlex Vasculitis (VAS) assay achieved IVDR-CE Mark. This means that the MosaiQ AiPlex VAS assay is now available for clinical use in the European Union and other countries accepting the IVDR-CE mark.
The MosaiQ AiPlex VAS assay is designed to improve time to results to support diagnosis of autoimmune vasculitis, while simplifying laboratory workflows. ANCA-associated vasculitides comprise three distinct syndromes – granulomatosis with polyangiitis (GPA, formerly known as Wegener’s granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly known as Churg-Strauss syndrome). If left untreated, Anti-GBM disease can lead to life-threatening consequences. Vasculitides are complex conditions that cause inflammation of blood vessel walls, potentially leading to severe organ and tissue damage. It can present as a medical emergency and varies significantly by vessel size, organ involvement, and clinical symptoms, making timely and accurate diagnosis challenging.
Health Technology Insights: Hopscotch Primary Care Is Delivering A New Level Of Access To Care For The Seniors It Serves
MosaiQ AiPlex VAS multiplex assay: Fast, Easy, Comprehensive
The MosaiQ AiPlex VAS assay enables simplified serological evaluation (rule in or rule out) of autoimmune vasculitis for healthcare providers. Using only 10μl of patient serum, the test provides results for three key autoantibody markers – MPO, PR3, and GBM – in a single, comprehensive report. These markers are aligned with current clinical best practices, including the 2022 ACR/EULAR guidelines for managing ANCA-associated vasculitis2-4 and KDIGO 2021 guideline for managing Glomerular Diseases.
Health Technology Insights: JotPsych Secures $5 Million Seed Round from Base10 Partners
“Our MosaiQ technology provides multiplexed test results fully automated and at speed, which shortens time to results and supports accelerated diagnosis of autoimmune diseases, improving patient outcomes and reducing healthcare costs. Achieving IVDR-CE Mark approval is a major step forward in our mission to bring best-in-class healthcare solutions to clinicians, labs – and most of all, patients across Europe. This milestone confirms our commitment to meeting the highest standards of safety, performance, and quality with yet another panel in our portfolio,” said Manuel O. Méndez, CEO of AliveDx.
The intuitive MosaiQ solution has been designed to provide simple workflow, fast results and actionable insights through its high throughput, automated multiplexing capability. Combining multiple relevant markers into one single test enables actionable insights for better patient care, as well as reducing significant hands-on time and minimizing consumable usage. To further simplify laboratory workflows, internal calibration of each microarray is embedded at the point of manufacture, thus saving time in the lab. All reagents and multiplex microarray magazines are equipped with RFID tags to aid automation, save time while avoiding manual errors.
Health Technology Insights: IQM LAUNCHES INDUSTRY-FIRST NURSE TARGETING PRODUCT FOR HEALTHCARE CLIENTS
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- PR Newswire
